Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Research Square|March 24, 2021
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVAljawharah Alrubayyi, Ester Gea-Mallorquí, Emma Touizer, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2021
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVAljawharah Alrubayyi, Ester Gea-Mallorquí, Emma Touizer, et al.
Nature Communications|October 6, 2021
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVAljawharah Alrubayyi, Ester Gea-Mallorquí, Emma Touizer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 14, 2019
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical TrialsPaul E Sax, Kristine M Erlandson, Jordan E Lake, et al.
Scientific Reports|November 4, 2023
Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1Aljawharah Alrubayyi, Emma Touizer, Dan Hameiri-Bowen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 14, 2021
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical TrialsKristine M Erlandson, Christoph C Carter, Kathleen Melbourne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 TrialMarcelo V Negrao, Alvaro G Paula, David Molkentine, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 19, 2023
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 TrialAbiu Sempere, Lambert Assoumou, Ana González-Cordón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2022
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized TrialLaura Waters, Lambert Assoumou, Ana González-Cordón, et al.
Pageof 11